• Citius Oncology flagged a Phase 1 study of LYMPHIR with Merck’s Keytruda for poster presentation at ASCO 2026.
• Results will be presented May 30, 2026; the study tested the combination in relapsed or refractory gynecologic cancers.
• Top-line findings showed signs of tumor shrinkage in some patients, with responses that tended to last, supporting further development interest.
• Safety signals were described as favorable, supporting the strategy of using LYMPHIR to potentially boost checkpoint inhibitor activity beyond CTCL.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.